10 Best Gene Therapy Stocks to Buy in 2026
Gene therapies aim to treat or prevent diseases by introducing new instructions in a patient’s cells to fix or replace the defective genes behind genetic disorders.
Solid Biosciences Inc. (SLDB)
Market is closed
Sector: Healthcare
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Perceptive Advisors Joseph Edelman | 11,906,646 | $85,727,851 | +1% | 1.68% |
| 2. | RA Capital Management Peter Kolchinsky | 9,339,978 | $67,247,842 | +61% | 0.71% |
| 3. | Siren L.L.C. Raymond Debbane | 7,690,405 | $55,370,916 | 1.53% | |
| 4. | Vestal Point Capital Ryan Wilder | 5,000,000 | $36,000,000 | -15% | 1.01% |
| 5. | Deep Track Capital David Kroin | 3,565,062 | $25,668,446 | 0.42% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $5.34 | 1,860 | $9,924.40 | 2,960 | 2025-03-11 | Filing | |
| $4.03 | 1,000,000 | $4,030,000.00 | 5,034,582 | 2025-02-19 | Filing | |
| $4.03 | 5,000,000 | $20,150,000.00 | 11,833,539 | 2025-02-19 | Filing | |
| $7.56 | 252,545 | $1,909,240.20 | 4,248,084 | 2025-02-18 | Filing | |
| $7.67 | 1,100 | $8,441.62 | 1,100 | 2024-06-07 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $5.82 | 16,644 | $96,923.01 | 235,405 | 2026-02-18 | Filing | |
| $5.82 | 4,134 | $24,073.52 | 74,318 | 2026-02-18 | Filing | |
| $5.82 | 2,658 | $15,478.33 | 27,474 | 2026-02-18 | Filing | |
| $5.82 | 3,616 | $21,057.05 | 72,638 | 2026-02-18 | Filing | |
| $5.82 | 7,469 | $43,494.23 | 105,077 | 2026-02-18 | Filing |
Institutional Investors' Holdings
Filing Period: Filing is Ongoing
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 1,417 | $14,156 | 0% | |
| 2. | 151 | $1,508 | 0% | |
| 3. | 107 | $1,069 | 0% |
News See All
Sarepta's Elevidys Safety Concerns Open Major Opportunity for Solid Biosciences' (SLDB) SGT-003 in Duchenne Therapy
Solid Biosciences Inc. (NASDAQ:SLDB) is one of the stocks that will double in 2026.
20 Stocks That Will Double in 2026
On December 8, Kevin Mahn of Hennion & Walsh appeared on CNBC's 'Closing Bell Overtime' to discuss the potential for another bullish year, but with more volatility.
Citi Initiates Coverage on Solid Biosciences Inc. (SLDB) with ‘Buy’ Rating and $14 PT
Citi initiated coverage on Solid Biosciences Inc. (NASDAQ:SLDB) with a ‘Buy’ rating, setting its price target at $14 on June 26, 2025.
7 Best Stocks to Invest in for a Quick Return
Going after quick returns in stock investing often means capitalizing on strong trends before they cool off.
14 Stocks With Heavy Insider Buying In 2024
Markets await latest inflation numbers and the debate regarding soft vs hard landing is expected to persist in the Wall Street for months to come.
Hedge Funds Have Never Been This Bullish On Solid Biosciences Inc. (SLDB)
In this article we will check out the progression of hedge fund sentiment towards Solid Biosciences Inc. (NASDAQ:SLDB) and determine whether it is a good investment right now.
Is SLDB A Good Stock To Buy Now?
In this article we will take a look at whether hedge funds think Solid Biosciences Inc. (NASDAQ:SLDB) is a good investment right now.
Solid Biosciences Inc. (SLDB): Hedge Fund Sentiment Unchanged
The latest 13F reporting period has come and gone, and Insider Monkey is again at the forefront when it comes to making use of this gold mine of data.
Is Solid Biosciences Inc. (SLDB) Going to Burn These Hedge Funds?
The Insider Monkey team has completed processing the quarterly 13F filings for the September quarter submitted by the hedge funds and other money managers included in our extensive database.
Hedge Fund Resource Center